Epstein-Barr virus latent membrane protein 2 (LMP2)

Epstein-Barr virus latent membrane protein 2 (LMP2) is a critical viral protein expressed during the latent phase of EBV infection, existing as two isoforms, LMP2A and LMP2B [1]. LMP2A is particularly significant as it functions as a constitutively active mimic of the B-cell receptor (BCR), utilizing its immunoreceptor tyrosine-based activation motif (ITAM) to recruit Lyn and Syk kinases, thereby promoting B-cell survival and preventing lytic reactivation [2]. This signaling activity bypasses the need for antigen stimulation, contributing to the persistence of the virus in the host's B-cell compartment and driving oncogenic transformation [3].\n\nIn the context of EBV-associated malignancies, such as nasopharyngeal carcinoma, Hodgkin lymphoma, and various post-transplant lymphoproliferative disorders, LMP2 is consistently expressed and serves as a major target for immunotherapy [4]. Because it is a foreign viral antigen, it provides a high degree of specificity for therapeutic intervention with minimal off-target effects on healthy human tissue [5]. Current clinical approaches primarily focus on the development of LMP2-specific cytotoxic T-lymphocytes (CTLs), CAR-T cells, and therapeutic vaccines designed to boost the host immune response against EBV-positive tumor cells [6].

Other names

EBV LMP2Latent membrane protein 2ALatent membrane protein 2BLMP2ALMP2BEpstein-Barr virus LMP2

Induction of antigen-specific cytotoxic T-lymphocyte (CTL) responses to selectively recognize and lyse cells expressing viral proteins, or inhibition of oncogenic signaling pathways mediated by the viral protein.